

Supplemental Material to:

Ana A Tula-Sanchez, Aaron P Havas, Peter J Alonge, Mary E Klein, Samantha R Doctor, William Pinkston, Betty J Glinsmann-Gibson, Lisa M Rimsza, and Catharine L Smith

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors


**Cancer Biology & Therapy 2013; 14(10)
<http://dx.doi.org/10.4161/cbt.25941>**

<http://www.landesbioscience.com/journals/cbt/article/25941/>

Supplementary Table 1 – p53 status of DLBCL cell lines examined in this study.

<i>Cell line</i>	<i>DLBCL subtype</i>	<i>PXD101 Response</i>	<i>p53 status</i>	<i>References</i>
SUDHL6	GCB	Apoptosis	mutant	(69)
OCI-Ly19	GCB	Apoptosis	wildtype	(69)
SUDHL4	GCB	G1 Arrest	wildtype	(73,74)
DB	GCB	Apoptosis	mutant	(69)
SUDHL8	GCB	G1 Arrest	mutant	(75)
OCI-Ly3	ABC	Apoptosis	wildtype	(73)
U2932	ABC	G1 Arrest	mutant	(76)


Tula-Sanchez et al
Supplemental Fig S1A-D



Supplemental Figure 1 - Expression of MYC, BCL2, and Rb mRNAs in DLBCL cell lines.


A, B.) Total RNA was extracted from untreated cells and subjected to RT-qPCR with primer sets specific for MYC or BCL2 (A) or Rb (B). GAPDH expression was also measured as representative of a housekeeping gene. Relative mRNA levels for each gene were calculated as described in Materials and Methods. C, D.) Total RNA was extracted from cells treated with PXD101 for 0, 2, 4, 8, 24, 48, and 72 h. Data from treated cells are expressed relative to untreated cells for each experiment. PXD101-sensitive cell lines are shown in (C) while PXD101-resistant cell lines are shown in (D). The results shown are from at least 3 independent experiments.

Tula-Sanchez et al
Supplemental Fig S2A,B,C




Supplemental Figure 2 - Regulation of D cyclin expression by PXD101 in resistant cell lines. Whole cell extracts were isolated from SUDHL4 (A), SUDHL8 (B), and U2932 (C) cells treated with PXD101 for the times shown. Western blotting was performed with antibodies against Cyclin D3, Cyclin D1 (U2932 only), and GAPDH. The results shown are representative of 3 independent experiments.

Tula-Sanchez et al
Supplemental Fig S3A,B,C



Supplemental Figure 3 - Regulation of p21 mRNA by PXD101 in sensitive and resistant DLBCL cell lines. Total RNA was extracted from cells treated with PXD101 for 0, 2, 4, 8, 24, 48, and 72 h and subjected to RT-qPCR with primers specific for p21 and GAPDH. Data from treated samples are expressed relative to untreated samples. The graphs shown the summary of results from 3-4 independent experiments. PXD101-sensitive cell lines are shown in (A). PXD101-resistant cell lines SUDHL4 and U2932 are shown in (B) and (C), respectively.



Supplemental Figure 4 - Regulation of PUMA by PXD101 and Doxorubicin in sensitive and resistant DLBCL cell lines with wt p53. SUDHL4 and OCI-Ly19 cells were treated with PXD101 or Doxorubicin (2mM) for 0, 8, and 24 h. Whole cell extracts were generated and subjected to Western blotting with antibodies against PUMA or GAPDH. A.) Representative western blot. B.) Graphic summary of the results from 3 independent experiments. Error bars represent SEM. * $p < 0.05$.